MSC Treatment

BIOLOGICAL3 trials

Sponsors

University of Cambridge, Universidad de los Andes, Chile, SBÜ Dr. Sadi Konuk Eğitim ve Araştırma Hastanesi

Conditions

Corona Virus InfectionCovid19Lupus Erythematosus, SystemicLupus GlomerulonephritisMultiple Organ FailureMultiple SclerosisPneumonia

Phase 1

Mesenchymal Stem Cells in Multiple Sclerosis (MSCIMS)

CompletedNCT00395200

University of CambridgeMultiple Sclerosis

Start: 2008-07-31End: 2010-12-31Updated: 2011-10-25

Clinical Use of Stem Cells for the Treatment of Covid-19

CompletedNCT04392778

SBÜ Dr. Sadi Konuk Eğitim ve Araştırma HastanesiCorona Virus Infection, Covid19, Multiple Organ Failure +1

Start: 2020-04-01End: 2020-11-30Updated: 2021-05-25

Phase 2

Mesenchymal Stromal Cells (MSC´s) in Renal Lupus

Universidad de los Andes, ChileLupus Erythematosus, Systemic, Lupus Glomerulonephritis

Start: 2019-04-02End: 2025-12-31Target: 39Updated: 2023-02-08

Related Papers

AUTOLOGOUS MESENCHYMAL STEM CELLS FOR THE TREATMENT OF SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS: AN OPEN–LABEL PHASE 2A PROOF–OF–CONCEPT STUDY

Journal of Neurology Neurosurgery & Psychiatry2013-10-0938 citations

Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study.

2012-01-10439 citations

The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessments.

2011-03-0283 citations